Search - tctmd.com

Displaying 321 - 340 of 386

Sort: Relevancy | Date

News Daily News

Oral Anticoagulation Underused in Japanese A-fib Patients Undergoing PCI

Caitlin E. Cox

April 30, 2014

News Daily News

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

L.A. McKeown

April 11, 2014

News Conference News ACC 2014

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

Yael L. Maxwell

March 31, 2014

News Daily News

DAPT Interruption At Least 1 Month After ZES Implantation Appears Safe

Yael L. Maxwell

February 17, 2014

News Daily News

Analysis Shows DES Reduce TVR but Not Mortality vs. BMS in Extreme Elderly

December 30, 2013

News Daily News

Los Hallazgos avalan una Duración de la Terapia Antiplaquetaria Doble mayor que 3 Meses en Pacientes SCA

L.A. McKeown

November 01, 2013

News Daily News

Findings Support DAPT Duration Longer Than 3 Months in ACS Patients

L.A. McKeown

November 01, 2013

Presentation TCT 2013

Optimal DAPT Duration Is Not Established: For Now Most Patients Should Stay on DAPT for at Least One Year!

Presenter: Edoardo Camenzind

October 31, 2013

Presentation TCT 2013

The DAPT Duration Dilemma: Recent Trials and Reasonable Guidelines for Clinical Practice

Presenter: Dean Kereiakes

October 31, 2013

Presentation TCT 2013

OPTIMIZE and ARTIC-INTERRUPTION: Perspectives on DAPT Duration after PCI

Presenter: Peter Wenaweser

October 31, 2013

News Conference News TCT 2013

OPTIMIZE: 3-Month DAPT Safe with ZES

October 31, 2013

News Industry News

New Study Demonstrates Potential Benefits of Shorter-Term Dual Antiplatelet Therapy in Patients Treated With a Second Generation Drug-Eluting Stent

October 31, 2013

News Conference News TCT 2013

Cre8, BioFreedom Polymer-Free DES Show Promise

October 28, 2013

Presentation

Short- vs. Long-term Duration of DAPT in Patients Treated for In-Stent Restenosis

Presenter: Gianluca Campo

October 23, 2013

News Daily News

Longer DAPT Duration Reduces Adverse Events After PCI for In-Stent Restenosis

Caitlin E. Cox

October 23, 2013

News Daily News

Long-term Aspirin as Effective as Dual Therapy in Uncomplicated DES Patients

Jason Kahn

October 11, 2013

News Conference News ESC 2013

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

Yael L. Maxwell

September 01, 2013

News Daily News

JAMA Review Tackles Intricacies of Medical Therapy After PCI

Caitlin E. Cox

July 11, 2013

News Industry News

CID releasesDemonstr8 randomised trialresults during Late Breaking Trials

May 22, 2013

News Industry News

CID SpA Sponsors a Major Symposium at EuroPCR 2013 on Thursday 23rd of May

May 17, 2013

Advertisement

Oral Anticoagulation Underused in Japanese A-fib Patients Undergoing PCI

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

DAPT Interruption At Least 1 Month After ZES Implantation Appears Safe

Analysis Shows DES Reduce TVR but Not Mortality vs. BMS in Extreme Elderly

Los Hallazgos avalan una Duración de la Terapia Antiplaquetaria Doble mayor que 3 Meses en Pacientes SCA

Findings Support DAPT Duration Longer Than 3 Months in ACS Patients

Optimal DAPT Duration Is Not Established: For Now Most Patients Should Stay on DAPT for at Least One Year!

The DAPT Duration Dilemma: Recent Trials and Reasonable Guidelines for Clinical Practice

OPTIMIZE and ARTIC-INTERRUPTION: Perspectives on DAPT Duration after PCI

OPTIMIZE: 3-Month DAPT Safe with ZES

New Study Demonstrates Potential Benefits of Shorter-Term Dual Antiplatelet Therapy in Patients Treated With a Second Generation Drug-Eluting Stent

Cre8, BioFreedom Polymer-Free DES Show Promise

Short- vs. Long-term Duration of DAPT in Patients Treated for In-Stent Restenosis

Longer DAPT Duration Reduces Adverse Events After PCI for In-Stent Restenosis

Long-term Aspirin as Effective as Dual Therapy in Uncomplicated DES Patients

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

JAMA Review Tackles Intricacies of Medical Therapy After PCI

CID releasesDemonstr8 randomised trialresults during Late Breaking Trials

CID SpA Sponsors a Major Symposium at EuroPCR 2013 on Thursday 23rd of May

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content